Compare AEO & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEO | CRSP |
|---|---|---|
| Founded | 1977 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.9B |
| IPO Year | 2004 | 2016 |
| Metric | AEO | CRSP |
|---|---|---|
| Price | $19.87 | $57.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 17 |
| Target Price | $21.09 | ★ $70.29 |
| AVG Volume (30 Days) | ★ 4.9M | 1.4M |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $5,547,236,000.00 | $289,590,000.00 |
| Revenue This Year | $5.22 | $807.72 |
| Revenue Next Year | $3.38 | $172.52 |
| P/E Ratio | $17.80 | ★ N/A |
| Revenue Growth | 4.10 | ★ 9169.85 |
| 52 Week Low | $9.27 | $33.03 |
| 52 Week High | $28.46 | $78.48 |
| Indicator | AEO | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 60.45 | 65.20 |
| Support Level | $15.82 | $51.64 |
| Resistance Level | $20.43 | $60.63 |
| Average True Range (ATR) | 0.71 | 2.44 |
| MACD | 0.48 | 1.13 |
| Stochastic Oscillator | 94.55 | 89.02 |
American Eagle Outfitters Inc is a specialty retailer. The company is engaged in the retail of apparel and accessories with company stores in the United States, Canada, Mexico, and Hong Kong. The Company leases all store premises, regional distribution facilities, some of its office space, and certain information technology and office equipment. American Eagle also has its online business. It operates in two segments: American Eagle and Aerie. The majority of its revenue comes from its primary brand, American Eagle, which offers an assortment of specialty apparel, accessories, and personal care products for women and men. Geographically, it generates the majority of its revenue from the United States.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.